A taste of the intelligence Theranostix produces, a monthly brief to keep you ahead of the European theranostics market — and full transparency on where our data comes from.
A 32-page sample of Theranostix intelligence: centre readiness by country, sponsor activity, pipeline maturity and the workforce constraints shaping PSMA-targeted RLT across nine markets. Enter your work email to download.
The next frontier after Lu-177 — who’s developing, and which centres can handle alpha.
Therapy beds, trained staff and referral pathways in the two largest markets.
What the acquisitions signal for site demand and competitive white-space.
The two questions every pharma buyer asks — “is the data credible?” and “is this compliant and independent?” — answered in full. This is the section your procurement and medical-legal teams will want.
Trial intelligence is drawn from public registries — ClinicalTrials.gov and the EU CTIS — plus institutional and other public sources. Centre and community signals come from the Nucleascope data backbone.
Readiness reflects observable theranostics activity and capability signals — isotope capability, therapy delivery, trial participation and more — combined into a transparent, defensible score. Methodology detail is available to licensees.
Data refreshes on a defined cadence by tier (monthly on Explorer; more frequently at higher tiers), with a “propose a correction” loop and human verification of high-stakes fields.
Public-source provenance; aggregated and anonymised community signals; no patient data, ever; EU-friendly data residency and documented security.
The clinician community that powers our data backbone (Nucleascope) remains free and editorially independent. Theranostix sells intelligence to companies — it does not promote therapies to prescribers.
Pipeline moves, readiness shifts and market signals — once a month, to your inbox.